Advertisement

International Journal of Hematology

, Volume 106, Issue 3, pp 426–430 | Cite as

Allogeneic hematopoietic stem cell transplantation for refractory mycosis fungoides (MF) and Sezary syndrome (SS)

  • Erden AtillaEmail author
  • Pinar Ataca Atilla
  • Sinem Civriz Bozdag
  • Meltem Kurt Yuksel
  • Selami Kocak Toprak
  • Pervin Topcuoglu
  • Bengu Nisa Akay
  • Hatice Sanli
  • Gunhan Gurman
  • Muhit Ozcan
Original Article

Abstract

Cutaneous T cell lymphoma is a heterogeneous group of lymphoproliferative disorders with different clinical behavior and prognosis in which malignant T cells accumulate in the skin. In the relapsed/refractory stage, treatment strategy varies depending on clinical perspective. We retrospectively evaluated advanced stage relapse or refractory mycosis fungoides and Sezary syndrome patients who underwent allogeneic hematopoietic stem cell transplantation (allo-HSCT) at our hospital. The overall response rate was 25%, while the disease progressed and relapsed after transplant in 38% of patients. Allo-HSCT may be a reasonable treatment option in the relapsed/refractory stage.

Keywords

Mycosis fungoides Sezary syndrome Allogeneic hematopoietic stem cell transplantation 

Notes

Compliance with ethical standards

Conflict of interest

None.

References

  1. 1.
    Masson AD, Beylot MD, Bouaziz JD, Latour P, Aubin F, Garciaz S. Allogeneic stem cell transplantation for advanced cutaneous lymphomas: a study from the French Society of Bone Marrow Transplantation and French Study Group on Cutaneous Lymphomas. Haematologica. 2014;99(3):527–34.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Duarte RF, Schmitz N, Servitje O, Sureda A. Haematopoietic stem cell transplantation for patients with primary cutaneous T-cell lymphoma. Bone Marrow Transplant. 2008;41:597–604.CrossRefPubMedGoogle Scholar
  3. 3.
    Wu PA, Kim YH, Lavori PW, Hoppe RT, Stockerl-Goldstein KE. A metaanalysis of patients receiving allogeneic or autologous hematopoietic stem cell transplant in mycosis fungoides and Sezary syndrome. Biol Blood Marrow Transplant. 2009;15:982–90.CrossRefPubMedGoogle Scholar
  4. 4.
    Willemze R, Jaffe ES, Burg G, Cerroni L, Berti E, Swerdlow SH, et al. WHO–EORTC classification for cutaneous lymphomas. Blood. 2005;105(10):3768–85.CrossRefPubMedGoogle Scholar
  5. 5.
    Kim YH, Willemze R, Pimpinelli N, Whittaker S, Olsen EA, Ranki A, et al. TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the Cutaneous Lymphoma Task Force of the European Organization of Research and Treatment of-Cancer (EORTC). Blood. 2007;110(2):479–84.CrossRefPubMedGoogle Scholar
  6. 6.
    Olsen EA, Whittaker S, Kim YH, Duvic M, Prince HM, Lessin SR, et al. Clinical end points and response criteria in mycosis fungoides and Sézary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer. J Clin Oncol. 2011;29(18):2598–607.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Lechowicz MJ, Lazarus HM, Carreras J, Laport GG, Cutler CS, Wiernik PH, et al. Allogeneic hematopoietic cell transplantation for mycosis fungoides and Sezary syndrome. Bone Marrow Transplant. 2014;49:1360–5.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Duvic M, Donato M, Dabaja B, Richmond H, Singh L, Wei W, et al. Total skin electron beam and non-myeloablative allogeneic hematopoietic stem-cell transplantation in advanced mycosis fungoides and Sezary syndrome. J Clin Oncol. 2010;28(14):2365–72.CrossRefPubMedGoogle Scholar
  9. 9.
    Duarte RF, Canals C, Onida F, Gabriel IH, Arranz R, Arcese W, et al. Allogeneic hematopoietic cell transplantation for patients with mycosis fungoides and Sézary syndrome: a retrospective analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol. 2010;28(29):4492–9.CrossRefPubMedGoogle Scholar
  10. 10.
    Polansky M, Talpur R, Daulat S, Hosing C, Dabaja B, Duvic M. Long term complete responses to combination therapies and allogeneic stem cell transplants in patients with Sezary syndrome. Clin Lymphoma Myeloma Leuk. 2015;15(5):e83–93.CrossRefPubMedGoogle Scholar
  11. 11.
    Duarte RF, Boumendil A, Onida F, Gabriel I, Arranz R, Arcese W, et al. Long-term outcome of allogeneic hematopoietic cell transplantation for patients with mycosis fungoides and Sézary syndrome: a European society for blood and marrow transplantation lymphoma working party extended analysis. J Clin Oncol. 2014;32(29):3347–8.CrossRefPubMedGoogle Scholar
  12. 12.
    Storb R, Gyurkocza B, Storer BE, Sorror ML, Blume K, Niederwieser D, et al. Graftversus-host disease and graft-versus-tumor effects after allogeneic hematopoietic cell transplantation. J Clin Oncol. 2013;31(12):1530–8.CrossRefPubMedGoogle Scholar
  13. 13.
    Herbert KE, Spencer A, Grigg A, Ryan G, McCormack C, Prince HM. Graft-versus lymphoma effect in refractory cutaneous T-cell lymphoma after reduced-intensity HLA-matched sibling allogeneic stem cell transplantation. Bone Marrow Transplant. 2004;34:521.CrossRefPubMedGoogle Scholar

Copyright information

© The Japanese Society of Hematology 2017

Authors and Affiliations

  • Erden Atilla
    • 1
    Email author
  • Pinar Ataca Atilla
    • 1
  • Sinem Civriz Bozdag
    • 1
  • Meltem Kurt Yuksel
    • 1
  • Selami Kocak Toprak
    • 1
  • Pervin Topcuoglu
    • 1
  • Bengu Nisa Akay
    • 2
  • Hatice Sanli
    • 1
    • 2
  • Gunhan Gurman
    • 1
  • Muhit Ozcan
    • 1
  1. 1.BMT Unit, Department of Hematology, Cebeci Hospital, School of MedicineAnkara UniversityAnkaraTurkey
  2. 2.Department of Dermatology, School of MedicineAnkara UniversityAnkaraTurkey

Personalised recommendations